PMV Pharma Q1 net loss $17.5M; Phase 2 interim data expected mid-2025

PMV Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.34

Phase 2 PYNNACLE interim analysis mid-2025; data for ~50 patients with ≥18 weeks follow-up.
Cash $165.8M as of March 31, 2025 vs $183.3M Dec 31, 2024; runway to end of 2026.
Net loss Q1 2025 $17.5M ($15.3M Q1 2024); R&D expenses $17.4M vs $13.2M.
G&A expenses decreased to $4.1M from $5.0M on reduced headcount and facility spend.
Rezatapopt discovery paper published in Cancer Discovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.